Shots:
- The EC has approved Verquvo (2.5/5/10 mg) in the EU for the treatment of symptomatic CHF in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event. The therapy is being jointly developed by both companies
- Merck has the commercial rights to Verquvo in the US and Bayer has the exclusive commercial rights in the ROW. Additionally, both companies share equally cost for the development of vericiguat
- Vericiguat is the sGC stimulator, received the US FDA’s approval in Jan’21 & MHLW approval in Jun’21. The therapy has also been submitted for marketing authorization in China along with multiple other countries globally
Click here to read full press release/ article | Ref: Businesswire| Image: The Conversation
The post Bayer and Merck’s Verquvo (vericiguat) Receives the EC’s Approval for the Treatment of Chronic Heart Failure first appeared on PharmaShots.
